Drug nanocrystals: A way toward scale-up

Saudi Pharmaceutical Journal

Volumn 24, Issue 4, 2016, Pages 386-404

  Raghava Srivalli, Kale Mohana ^a   Mishra, Brahmeshwar ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Bridging; Experimental design; Nanocrystals; Smartcrystals; Stabilizers; Upscaling

Indexed keywords

ACETONE; APIGENIN; DISPERSANT; DODECYL SULFATE SODIUM; DRUG; FENOFIBRATE; GLASS; HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL; MANNITOL; MELOXICAM; NANOCRYSTAL; NEVIRAPINE; NIFEDIPINE; NITRENDIPINE; NVS 102; PHENYTOIN; POLOXAMER; POLYSORBATE 80; POLYSTYRENE; POLYVINYL ALCOHOL; PRANLUKAST; PYRROLIDINE DERIVATIVE; RESIN; STABILIZING AGENT; STAINLESS STEEL; SURFACTANT; UNCLASSIFIED DRUG; WATER; YTTRIUM; ZIRCONIUM;

ANALYTIC METHOD; ANALYTICAL EQUIPMENT; BATCH PROCESS; COMPARATIVE STUDY; CONTINUOUS PROCESS; CRYSTALLIZATION; DRUG FORMULATION; DRUG STABILITY; FREEZE DRYING; HIGH PRESSURE HOMOGENIZATION; IN VITRO STUDY; IN VIVO STUDY; LARGE SCALE PRODUCTION; LIPOPHILICITY; LIQUID; MORPHOLOGY; NANOPHARMACEUTICS; NANOSUSPENSION; PARTICLE SIZE; PRECIPITATION; PRECLINICAL STUDY; PRESSURE; PROCESS OPTIMIZATION; PROCESSING; REVIEW; SCALE UP; SOLID STATE; SURFACE CHARGE; SUSPENSION; TECHNOLOGY; WET BALL MILLING; WET MILLING;

EID: 84998679675     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2014.04.007     Document Type: Review

References (60)

1. Abdelwahed, W., Degobert, G., Stainmesse, S., Fessi, H., Freeze-drying of nanoparticles formulation, process and storage considerations. Adv. Drug Deliv. Rev. 58 (2006), 1688–1713.
2. Ali, H.S.M., York, P., Ali, A.M.A., Blagden, N., Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling. J. Control Release 149 (2011), 175–181.
3. Cerdeira, A.M., Mazzotti, M., Gander, B., Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability. Int. J. Pharm. 396 (2010), 210–218.
4. Chan, H., Kwok, P.C.L., Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Deliv. Rev. 63 (2011), 406–416.
5. de Waard, H., Grasmeijer, N., Hinrichs, W.L.J., Eissens, A.C., Pfaffenbach, P.P.F., Frijlink, H.W., Preparation of drug nanocrystals by controlled crystallization: application of a 3-way nozzle to prevent premature crystallization for large scale production. Eur. J. Pharm. Sci. 38 (2009), 224–229.
6. Deschamps, B., Musaji, N., Gillespie, J.A., Food effect on the bioavailability of two distinct formulations of megesterol acetate oral suspension. Int. J. Nanomed. 4 (2009), 185–192.
7. Dong, Y., Ng, W.K., Hu, J., Shen, S., Tan, R.B.H., A continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs. Int. J. Pharm. 386 (2010), 256–261.
8. Eerdenbrugh, B.V., Mooter, G.V., Augustijns, P., Top-down production of drug nanocrystals nanosuspension stabilization, miniaturization and transformation into solid products. Int. J. Pharm. 364 (2008), 64–75.
9. Eerdenbrugh, B.V., Stuyven, B., Froyen, L., Humbeeck, J.V., Martens, J.A., Augustijns, P., Mooter, G.V.D., Downscaling drug nanosuspension production: processing aspects and physicochemical characterization. AAPS PharmSciTech 10 (2009), 44–53.
10. El-Gendy, N., Pornputtapitak, W., Berkland, C., Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols. Eur. J. Pharm. Sci. 44 (2011), 522–533.
11. Faure, A., York, P., Rowe, R.C., Process control and scale-up of pharmaceutical wet granulation processes: a review. Eur. J. Pharm. Biopharm. 52 (2001), 269–277.
12. Ganta, S., Paxton, J.W., Baguley, B.C., Garg, S., Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int. J. Pharm. 367 (2009), 179–186.
13. Gao, L., Zhang, D., Chen, M., Duan, C., Daia, W., Jia, L., Zhao, W., Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int. J. Pharm. 355 (2008), 321–327.
14. Gao, L., Zhang, D., Chen, M., Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J. Nanopart. Res. 10 (2008), 845–862.
15. Gasper, R.S., 2010. Nanomedicines on the market and in development: Nanoparticles Ist international workshop on nanomedicine, European medicines agency, 2nd, 3rd, September 2010. London, UK. Available at: < http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2010/09/WC500096193.pdf>. (accessed 28.01.14).
16. Ghosh, I., Schenck, D., Bose, S., Ruegger, C., Optimization of formulation and process parameters for the production of nanosuspension by wet media milling technique: effect of vitamin E TPGS and nanocrystal particle size on oral absorption. Eur. J. Pharm. Sci. 47 (2012), 718–728.
17. Hanafy, A., Spahn-Langguth, H., Vergnault, G., Grenier, P., Tubic Grozdanis, M., Lenhardt, T., Langguth, P., Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv. Drug Deliv. Rev. 59 (2007), 419–426.
18. Hu, J., Ng, W.K., Dong, Y., Shen, S., Tan, R.B.H., Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying. Int. J. Pharm. 404 (2011), 198–204.
19. Jacobs, C., Müller, R.H., Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 19 (2002), 189–194.
20. Kakrana, M., Shegokar, R., Sahoo, N.G., Shaal, L.A., Li, L., Müller, R.H., Fabrication of quercetin nanocrystals: comparison of different methods. Eur. J. Pharm. Biopharm. 80 (2012), 113–121.
21. Kassem, M.A., Rahman, A.A.A., Ghorab, M.M., Ahmed, M.B., Khalil, R.M., Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int. J. Pharm. 340 (2007), 126–133.
22. Kayser, O., A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. Int. J. Pharm. 214 (2001), 83–85.
23. Kayser, O., Olbrich, C., Yardley, V., Kiderlen, A.F., Croft, S.L., Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm. 254 (2003), 73–75.
24. Keck, C.M., Müller, R.H., Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm. 62 (2006), 3–16.
25. Keck, C., Kobierski, S., Mauludin, R., Müller, R.H., Second generation of drug nanocrystals for delivery of poorly soluble drugs: smartCrystals technology. Dosis 24 (2008), 124–128.
26. Kipp, J.E., The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 284 (2004), 109–122.
27. Kocbek, P., Baumgartner, S., Kristl, J., Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int. J. Pharm. 312 (2006), 179–186.
28. Levin, M., Pharmaceutical Process Scale-up. 2002, Marcel Dekker, New York.
29. Lieberman, H.A., Rioger, M.M., Banker, G.S., Pharmaceutical dosage forms: disperse systems, vol. 3. 1998, Marcel Dekker, New York.
30. Mauludin, R., Müller, R.H., Keck, C.M., Development of an oral rutin nanocrystal formulation. Int. J. Pharm. 370 (2009), 202–209.
31. Merisko-Liversidge, E., Liversidge, G., Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 36 (2008), 43–48.
32. Merisko-Liversidge, E., Liversidge, G.G., Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv. Drug Deliv. Rev. 63 (2011), 427–440.
33. Merisko-Liversidge, E., Liversidge, G.G., Cooper, E.R., Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18 (2003), 113–120.
34. Mishra, P.R., Shaal, L.A., Müller, R.H., Keck, C.M., Production and characterization of hesperetin nanosuspensions for dermal delivery. Int. J. Pharm. 371 (2009), 182–189.
35. Mitri, K., Shegokar, R., Gohla, S., Anselmi, C., Müller, R.H., Lutein nanocrystals as antioxidant formulation for oral and dermal delivery. Int. J. Pharm. 420 (2011), 141–146.
36. Moeschwitzer, J., Nanotechnology: particle size reduction technologies in the pharmaceutical development process. Am. Pharm. Rev. 13 (2010), 54–59.
37. Moeschwitzer, J., The role of particle size analysis in the development process of nanosized drug products. Am. Pharm. Rev. 13 (2010), 95–101.
38. Möschwitzer, J.P., Drug nanocrystals in the commercial pharmaceutical development process. Int. J. Pharm. 453 (2013), 142–156.
39. Muller, R.H., Jacobs, C., Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int. J. Pharm. 237 (2002), 151–161.
40. Müller, R.H., Jacobs, C., Kayser, O., Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47 (2001), 3–19.
41. Niwa, T., Miura, S., Danjo, K., Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies – development of particle design method. Int. J. Pharm. 405 (2011), 218–227.
42. Patravale, V.B., Date, A.A., Kulkarni, R.M., Nanosuspensions a promising drug delivery strategy. J. Pharm. Pharmacol. 56 (2004), 827–840.
43. Quan, P., Xia, D., Piao, H., Piao, H., Shi, K., Jia, Y., Cui, F., Nitrendipine nanocrystals: its preparation, characterization, and in vitro–in vivo evaluation. AAPS PharmSciTech 12 (2011), 1136–1143.
44. Rabinow, B., Kipp, J., Papadopoulos, P., Wong, J., Glosson, J., Gass, J., Sun, C.S., Wielgos, T., White, R., Cook, C., Barker, K., Wood, K., Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int. J. Pharm. 339 (2007), 251–260.
45. Salazar, J., Ghanem, A., Müller, R.H., Möschwitzer, J.P., Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches. Eur. J. Pharm. Biopharm. 81 (2012), 82–90.
46. Salazar, J., Müller, R.H., Möschwitzer, J.P., Application of the combinative particle size reduction technology H42 to produce fast dissolving glibenclamide tablets. Eur. J. Pharm. Sci. 49 (2013), 565–577.
47. Shaal, L.A., Müller, R.H., Shegokar, R., SmartCrystal combination technology – scale up from lab to pilot scale and long term stability. Pharmazie 65 (2010), 877–884.
48. Shaal, L.A., Shegokar, R., Müller, R.H., Production and characterization of antioxidant apigenin nanocrystals as a novel UV skin protective formulation. Int. J. Pharm. 420 (2011), 133–140.
49. Sharma, P., Zujovic, Z.D., Bowmaker, G.A., Denny, W.A., Garg, S., Evaluation of a crystalline nanosuspension: polymorphism, process induced transformation and in vivo studies. Int. J. Pharm. 408 (2011), 138–151.
50. Shegokar, R., Müller, R.H., Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int. J. Pharm. 399 (2010), 129–139.
51. Shegokar, R., Singh, K.K., Müller, R.H., Nevirapine nanosuspension: comparative investigation of production methods. Nanotechnol. Dev. 1 (2011), 16–22.
52. Shen, L., Wu, F.L., Nanomedicines in renal transplant rejection—focus on sirolimus. Int. J. Nanomed. 2 (2007), 25–32.
53. Singare, D.S., Marella, S., Gowthamrajan, K., Kulkarni, G.T., Vooturi, R., Rao, P.S., Optimization of formulation and process variable of nanosuspension: an industrial perspective. Int. J. Pharm. 402 (2010), 213–220.
54. Singh, S.K., Srinivasan, K.K., Gowthamarajan, K., Singare, D.S., Prakash, D., Gaikwad, N.B., Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide. Eur. J. Pharm. Biopharm. 78 (2011), 441–446.
55. Sinha, B., Müller, R.H., Möschwitzer, J.P., Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int. J. Pharm. 453 (2013), 126–141.
56. Srivalli K.M.R. and Mishra B., 2014 Drug nanocrystals: Basic quadruple prerequisites for formulation development and upscalability, submitted for publication, Manuscript number SPJ-D-14-00281.
57. Venkataraman, S., Hedrick, J.L., Ong, Z.Y., Yang, C., Rachel Ee, P.L., Hammond, P.T., Yang, Y.Y., The effects of polymeric nanostructure shape on drug delivery. Adv. Drug Deliv. Rev. 63 (2011), 1228–1246.
58. Wu, Y., Loper, A., Landis, E., Hettrick, L., Novak, L., Lynn, K., Chen, C., Thompson, K., Higgins, R., Batra, U., Shelukar, S., Kwei, G., Storey, D., The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285 (2004), 135–146.
59. Yang, W., Johnston, K.P., Williams, R.O., Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur. J. Pharm. Biopharm. 75 (2010), 33–41.
60. Zhang, J., Wu, L., Chan, H., Watanabe, W., Formation, characterization, and fate of inhaled drug nanoparticles. Adv. Drug Deliv. Rev. 63 (2011), 441–455.